Trustees of Columbia University in the City of New York Purchases New Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Trustees of Columbia University in the City of New York purchased a new stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 192,973 shares of the company's stock, valued at approximately $328,000. Vigil Neuroscience accounts for about 0.1% of Trustees of Columbia University in the City of New York's investment portfolio, making the stock its 7th biggest holding. Trustees of Columbia University in the City of New York owned approximately 0.47% of Vigil Neuroscience as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Cubist Systematic Strategies LLC increased its position in Vigil Neuroscience by 53.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock worth $41,000 after acquiring an additional 8,358 shares during the period. Jane Street Group LLC bought a new stake in Vigil Neuroscience in the 4th quarter valued at $83,000. Barclays PLC increased its holdings in Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after buying an additional 19,436 shares during the period. Northern Trust Corp increased its holdings in Vigil Neuroscience by 29.0% in the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after buying an additional 14,572 shares during the period. Finally, Boothbay Fund Management LLC bought a new stake in Vigil Neuroscience in the 4th quarter valued at $249,000. Institutional investors own 83.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on VIGL. William Blair raised shares of Vigil Neuroscience to a "strong-buy" rating in a report on Thursday, April 24th. Wedbush restated an "outperform" rating and issued a $13.00 target price on shares of Vigil Neuroscience in a research note on Monday, May 5th. HC Wainwright reduced their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Friday, March 14th. Finally, Guggenheim reiterated a "buy" rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Vigil Neuroscience presently has a consensus rating of "Buy" and a consensus target price of $16.25.

Vigil Neuroscience Price Performance

Shares of NASDAQ VIGL traded down $0.17 during mid-day trading on Wednesday, hitting $2.31. The company's stock had a trading volume of 46,984 shares, compared to its average volume of 478,058. The stock has a market cap of $107.81 million, a price-to-earnings ratio of -1.12 and a beta of 1.90. Vigil Neuroscience, Inc. has a one year low of $1.31 and a one year high of $6.06. The company's fifty day simple moving average is $1.95 and its 200-day simple moving average is $2.24.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.04. On average, sell-side analysts predict that Vigil Neuroscience, Inc. will post -2.07 EPS for the current year.

Vigil Neuroscience Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.